
tella, Inc.
Share · JP3545900007 (XTKS)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of tella, Inc.
No Price
Company Profile for tella, Inc. Share
tella, Inc. researches and develops regenerative and cell medicines. The company offers techniques and operational knowhow associated with dendritic cell vaccine therapy to affiliated medical institutions for the treatment of cancer. It is also involved in the provision of consultation services on the establishment and maintenance of cell processing centers, and on introduction of management systems for cell cultivation; and lease of standard operating procedure and regular checks on manufacturing operation management and training of cell cultivation technicians. In addition, the company provides consultation services on training of expertise regarding treatment practice; and support services for the assessment of therapies, documentation required for treatment practice, and cognition and information providing activities for physicians and patients. tella, Inc. was founded in 2004 and is based in Tokyo, Japan.
Company Data
Name tella, Inc.
Company tella, Inc.
Website
https://www.tella.jp
Primary Exchange
Tokyo
ISIN JP3545900007
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Yuichiro Yazaki
Country Japan
Currency JPY
Employees 0,0 T
Address Mitsuihanagiri Building, 160-0023 Tokyo
IPO Date 2009-03-26
Dividends from 'tella, Inc.'
| Ex-Date | Dividend per Share |
|---|---|
| 26.12.2012 | 0,80 JPY |
| 28.12.2010 | 0,60 JPY |
Ticker Symbols
| Name | Symbol |
|---|---|
| Tokyo | 2191.T |
More Shares
Investors who hold tella, Inc. also have the following shares in their portfolio:

